Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M72/AS01E-4 Mtb Vaccine in Adolescents and Adults
NCT06062238Phase 3Active, not recruiting
- Sponsor
- Gates Medical Research Institute
- Start
- Mar 2024
- Primary completion
- Apr 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of M72/AS01E in Tuberculosis (TB) (2 arms), sponsored by Gates Medical Research Institute. Primary endpoint: Number of participants with laboratory-confirmed pulmonary tuberculosis (TB) at Month 49. Started Mar 2024; status: active, not recruiting.
02
Drugs
M72/AS01E
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT06062238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06062238.